Market Overview

Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation

Related ICPT
NASH Sympathy Plays On Tobira Therapeutics Deal
Thursday Morning's Top Earnings Reports
Gilead NASH Drug 'Active And Promising,' But Lagging Intercept (Investor's Business Daily)

In a note released Monday morning, Deutsche Bank analyst Alethia Young initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy rating and a $395 price target.

Young noted that Intercept is in the process of developing its lead asset OCA for the treatment of PBC and NASH.

Looking a head, Young wrote, "We think a stat sig trend on NASH clearance is essential for accelerated FDA approval and to remain competitive."

Young added, " We think shares currently reflect ~35% chance of success for NASH. We see some downside protection in the fact that if NASH fails in Ph2b, the co will likely price PBC higher."

Young is forecasting a price range of $336-$404 per share on good data and $110-$146 per share on bad data.

Shares of Intercept are up 3.4 percent at $229.77.

Latest Ratings for ICPT

Aug 2016OppenheimerMaintainsOutperform
Jul 2016Cantor FitzgeraldInitiates Coverage onSell
May 2016Goldman SachsMaintainsNeutral

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Alethia Young Deutsche BankAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (ICPT)

View Comments and Join the Discussion!